FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Willem Den Otter

Research Profile

Chemicals & Drugs

Living Beings

Disorders

Procedures

Physiology

Cytotoxicity, Immunologic

Anatomy

Co-author Network

Publications

TOP 3
Willem Den Otter; Zygmunt Dobrowolski; Rimantas Eidukevicius; Ronald Ter Haar; John J L Jacobs; Feliksas Jankevicius; Jan W Koten; Waclaw Lipczynski; Vita Pasukoniene; R Jeroen A Van Moorselaar; Dainius Characiejus; Theo M de Reijke
Role of Marker Lesion when Applying Intravesical Instillations of IL-2 for Non-muscle-invasive Bladder Cancer Comparison of the Therapeutic Effects in Two Pilot Studies.
Dainius Characiejus; Vita Pasukoniene; John J L Jacobs; Rimantas Eidukevicius; Feliksas Jankevicius; Neringa Dobrovolskiene; Mykolas Mauricas; R Jeroen A Van Moorselaar; Willem Den Otter
Prognostic significance of peripheral blood CD8highCD57+ lymphocytes in bladder carcinoma patients after intravesical IL-2.
Dainius Characiejus; John J L Jacobs; Vita Pašukonienė; Nijolė Kazlauskaitė; Vita Danilevičiūtė; Mykolas Mauricas; Willem Den Otter
Prediction of response in cancer immunotherapy.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Willem Den Otter (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Willem Den Otter; Zygmunt Dobrowolski; Rimantas Eidukevicius; Ronald Ter Haar; John J L Jacobs; Feliksas Jankevicius; Jan W Koten; Waclaw Lipczynski; Vita Pasukoniene; R Jeroen A Van Moorselaar; Dainius Characiejus; Theo M de Reijke
Role of Marker Lesion when Applying Intravesical Instillations of IL-2 for Non-muscle-invasive Bladder Cancer Comparison of the Therapeutic Effects in Two Pilot Studies.
Anticancer research 2013;33(5):2099-105.
2011: Dainius Characiejus; Vita Pasukoniene; John J L Jacobs; Rimantas Eidukevicius; Feliksas Jankevicius; Neringa Dobrovolskiene; Mykolas Mauricas; R Jeroen A Van Moorselaar; Willem Den Otter
Prognostic significance of peripheral blood CD8highCD57+ lymphocytes in bladder carcinoma patients after intravesical IL-2.
Anticancer research 2011;31(2):699-703.
2011: Dainius Characiejus; John J L Jacobs; Vita Pašukonienė; Nijolė Kazlauskaitė; Vita Danilevičiūtė; Mykolas Mauricas; Willem Den Otter
Prediction of response in cancer immunotherapy.
Anticancer research 2011;31(2):639-47.
2009: john jacobs; Dainius Characiejus; Rik J Scheper; Rachel J E Stewart; Jurgen F V Tan; Radosveta Tomova; Zachary Krastev; Willem Den Otter
The Amiens Strategy: small phase III trials for clinically relevant progress in the war against cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(18):3062-3; author reply 3063-4.
2008: Willem Den Otter; john jacobs; Jan J Battermann; Gerrit Jan Hordijk; Zachary Krastev; Ekaterina V Moiseeva; Rachel J E Stewart; Paul G P M Ziekman; Jan-Willem Koten
Local therapy of cancer with free IL-2.
Cancer immunology, immunotherapy : CII 2008;57(7):931-50.
2006: R J E Stewart; F W G Hill; Agnieszka Masztalerz; john jacobs; Jan-Willem Koten; Willem Den Otter
Treatment of ocular squamous cell carcinomas in cattle with interleukin-2.
The Veterinary record 2006;159(20):668-72.
2006: Radosveta Tomova; Javor Pomakov; john jacobs; Dimcho Adjarov; Svetlana Popova; Iskra Altankova; Willem Den Otter; Zachary Krastev
Changes in cytokine profile during local IL-2 therapy in cancer patients.
Anticancer research 2006;26(3A):2037-47.
2005: Natalya Mushenkova; Ekaterina Moiseeva; Alexandra Chaadaeva; Willem Den Otter; Elena Svirshchevskaya
Antitumor effect of double immunization of mice with mucin 1 and its coding DNA.
Anticancer research 2005;25(6B):3893-8.
2005: Zachary Krastev; V Koltchakov; R Tomova; S Deredjian; A Alexiev; D Popov; B Tomov; Jan-Willem Koten; john jacobs; Willem Den Otter
Locoregional IL-2 low dose applications for gastrointestinal tumors.
World journal of gastroenterology : WJG 2005;11(35):5525-9.
2005: john jacobs; Gerrit Jan Hordijk; Ina M Jürgenliemk-Schulz; Chris H J Terhaard; Jan-Willem Koten; Jan J Battermann; Willem Den Otter
Treatment of stage III-IV nasopharyngeal carcinomas by external beam irradiation and local low doses of IL-2.
Cancer immunology, immunotherapy : CII 2005;54(8):792-8.
2005: Rachel J E Stewart; Agnieszka Masztalerz; john jacobs; Willem Den Otter
Local interleukin-2 and interleukin-12 therapy of bovine ocular squamous cell carcinomas.
Veterinary immunology and immunopathology 2005;106(3-4):277-84.
2005: Ekaterina Moiseeva; Eugenia Rapoport; Nicolai V Bovin; Anatoly I Miroshnikov; A V Chaadaeva; M S Krasilshschikova; Vladimir Bojenko; Caspaar Bijleveld; Jaap E Van Dijk; Willem Den Otter
Galectins as markers of aggressiveness of mouse mammary carcinoma: towards a lectin target therapy of human breast cancer.
Breast cancer research and treatment 2005;91(3):227-41.
2005: Gert Bos; Wim E Hennink; Linda A Brouwer; Willem Den Otter; Theo F J Veldhuis; Cornelus F van Nostrum; Marja J A van Luyn
Tissue reactions of in situ formed dextran hydrogels crosslinked by stereocomplex formation after subcutaneous implantation in rats.
Biomaterials 2005;26(18):3901-9.
2004: Halina Kusnierczyk; Elzbieta Pajtasz-Piasecka; Jan-Willem Koten; Caspaar Bijleveld; Krzysztof Krawczyk; Willem Den Otter
Further development of local IL-2 therapy of cancer: multiple versus single IL-2 treatment of transplanted murine colon carcinoma.
Cancer immunology, immunotherapy : CII 2004;53(5):445-52.
2004: Gert Bos; john jacobs; Jan-Willem Koten; Sophie R Van Tomme; Theo F J Veldhuis; Cornelus F van Nostrum; Willem Den Otter; Wim E Hennink
In situ crosslinked biodegradable hydrogels loaded with IL-2 are effective tools for local IL-2 therapy.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 2004;21(4):561-7.
2003: Jan-Willem Koten; Marja J A van Luyn; Jenny A Cadée; Linda A Brouwer; Wim E Hennink; C Bijleveld; Willem Den Otter
IL-2 loaded dextran microspheres with attractive histocompatibility properties for local IL-2 cancer therapy.
Cytokine 2003;24(3):57-66.
2003: Zachary Krastev; V Koltchakov; D Popov; A Alexiev; Jan-Willem Koten; Willem Den Otter
A case of hepatocellular carcinoma (HCC): treatment with local application of alcohol and interleukin 2 (IL-2).
Hepato-gastroenterology 2003;50(53):1647-9.
2003: Ekaterina Moiseeva; Irina B Merkulova; Caspaar Bijleveld; Jan-Willem Koten; Anatoly I Miroshnikov; Willem Den Otter
Therapeutic effect of a single peritumoural dose of IL-2 on transplanted murine breast cancer.
Cancer immunology, immunotherapy : CII 2003;52(8):487-96.
2003: Agnieszka Masztalerz; Nico van Rooijen; Willem Den Otter; Linda A Everse
Mechanisms of macrophage cytotoxicity in IL-2 and IL-12 mediated tumour regression.
Cancer immunology, immunotherapy : CII 2003;52(4):235-42.
2003: T J P Spoormakers; Wim R Klein; john jacobs; Th S G A M Van Den Ingh; Jan-Willem Koten; Willem Den Otter
Comparison of the efficacy of local treatment of equine sarcoids with IL-2 or cisplatin/IL-2.
Cancer immunology, immunotherapy : CII 2003;52(3):179-84.
2002: Anton H C Baselmans; Jan-Willem Koten; Jan J Battermann; Jaap E Van Dijk; Willem Den Otter
The mechanism of regression of solid SL2 lymphosarcoma after local IL-2 therapy.
Cancer immunology, immunotherapy : CII 2002;51(9):492-8.
2002: Annette C Moll; Saskia M Imhof; Lex Bouter; Willem Den Otter; Jan-Willem Koten
An infant with Down syndrome and retinoblastoma. A possible non-fortuitous association.
Ophthalmic genetics 2002;23(2):135-6.
2002: Cornelis J De Groot; Jenny A Cadée; Jan-Willem Koten; Wim E Hennink; Willem Den Otter
Therapeutic efficacy of IL-2-loaded hydrogels in a mouse tumor model.
International journal of cancer. Journal international du cancer 2002;98(1):134-40.
2002: Jenny A Cadée; Cornelis J De Groot; Wim Jiskoot; Willem Den Otter; Wim E Hennink
Release of recombinant human interleukin-2 from dextran-based hydrogels.
Journal of controlled release : official journal of the Controlled Release Society 2002;78(1-3):1-13.
2001: Jenny A Cadée; Mies J van Steenbergen; Cees Versluis; albert heck; Willy J M Underberg; Willem Den Otter; Wim Jiskoot; Wim E Hennink
Oxidation of recombinant human interleukin-2 by potassium peroxodisulfate.
Pharmaceutical research 2001;18(10):1461-7.
2001: Jenny A Cadée; Linda A Brouwer; Willem Den Otter; Wim E Hennink; Marja J A van Luyn
A comparative biocompatibility study of microspheres based on crosslinked dextran or poly(lactic-co-glycolic)acid after subcutaneous injection in rats.
Journal of biomedical materials research 2001;56(4):600-9.
2001: Zachary Krastev; V Koltchakov; N Vladov; D Popov; A Milev; Jan-Willem Koten; Willem Den Otter
A mesothelioma that is sensitive to locally applied IL-2.
Cancer immunology, immunotherapy : CII 2001;50(4):226-7.
2001: Cornelis J De Groot; Marja J A van Luyn; W N Van Dijk-Wolthuis; Jenny A Cadée; Josée Plantinga; Willem Den Otter; Wim E Hennink
In vitro biocompatibility of biodegradable dextran-based hydrogels tested with human fibroblasts.
Biomaterials 2001;22(11):1197-203.
2000: Robert J J van Es; A H Baselmans; Jan-Willem Koten; Jaap E Van Dijk; Ron Koole; Willem Den Otter
Perilesional IL-2 treatment of a VX2 head-and-neck cancer model can induce a systemic anti-tumour activity.
Anticancer research 2000;20(6B):4163-70.
2000: Jenny A Cadée; Marja J A van Luyn; Linda A Brouwer; Josée Plantinga; Pauline B van Wachem; Cornelis J De Groot; Willem Den Otter; Wim E Hennink
In vivo biocompatibility of dextran-based hydrogels.
Journal of biomedical materials research 2000;50(3):397-404.
1999: Willem Den Otter
Evaluation: complementarity and contradictoriness of cancer theories. A genetic perspective.
Anticancer research 1999;19(6A):4913-4.
1999: Willem Den Otter; Jan-Willem Koten
A 4-mutation model of carcinogenesis for tumour suppressor genes.
Anticancer research 1999;19(6A):4845-52.
1999: Jan-Willem Koten; H Beukers; Willem Den Otter
History of cancer research in nosological perspective.
Anticancer research 1999;19(6A):4613-26.
1999: Willem Den Otter; R Root-Bernstein; Jan-Willem Koten
What is cancer? Theories on carcinogenesis.
Anticancer research 1999;19(6A):4601-2.
1999: Jan-Willem Koten; Willem Den Otter
Suggestion for IL-2 treatment of conjunctival squamous carcinoma.
The British journal of ophthalmology 1999;83(8):995-6.
1999: Willem Den Otter; L Balemans; Jan J Battermann; MR Bernsen; J A Cadee; Z Dobrowolski; Linda A Everse; Lucja Fiszer-Maliszewska; R Gavhumende; J W De Groot; K De Groot; Wim E Hennink; F W G Hill; I Jurgenliemp-Schulz; Wim R Klein; Jan-Willem Koten; R A Maas; Peter A Steerenberg; R Stewart; M Zembala
Local low-dose IL-2 therapy.
Hepato-gastroenterology 1999;46 Suppl 1():1280-6.
1999: Lucja Fiszer-Maliszewska; Willem Den Otter; M Mordarski
Effect of local interleukin-2 treatment on spontaneous tumours of different immunogenic strength.
Cancer immunology, immunotherapy : CII 1999;47(6):307-14.
1998: A W Brinkert; Annette C Moll; M J Jager; Willem Den Otter; Jan-Willem Koten; J A J Faber; KE Tan
Distribution of tumors in the retina in hereditary retinoblastoma patients.
Ophthalmic genetics 1998;19(2):63-7.
1998: Willem Den Otter; Z Dobrowolski; A Bugajski; B Papla; A P Van Der Meijden; Jan-Willem Koten; T A Boon; M Siedlar; M Zembala
Intravesical interleukin-2 in T1 papillary bladder carcinoma: regression of marker lesion in 8 of 10 patients.
The Journal of urology 1998;159(4):1183-6.
1998: MR Bernsen; Alike W van der Velden; Linda A Everse; Hub F J Dullens; Willem Den Otter; A P Heintz
Interleukin-2: hope in cases of cisplatin-resistant tumours.
Cancer immunology, immunotherapy : CII 1998;46(1):41-7.
1998: Lucja Fiszer-Maliszewska; Willem Den Otter; J A Madej; M Mordarski
Therapeutic potential of biological response modifiers against transplantable mouse tumors of spontaneous origin. II. Local interleukin 2 treatment of tumors of different immunogenic strength.
Archivum immunologiae et therapiae experimentalis 1998;46(5):293-300.
1997: Annette C Moll; Saskia M Imhof; E M Bleeker-Wagemakers; Willem Den Otter; Lex Bouter; Jan-Willem Koten; KE Tan
Prevalence of mental retardation in patients with hereditary retinoblastoma.
Ophthalmic genetics 1997;18(4):217-20.
1997: P L P Van Loo; Linda A Everse; MR Bernsen; Vera Baumans; Ludo J Hellebrekers; Cas L J J Kruitwagen; Willem Den Otter
Analgesics in mice used in cancer research: reduction of discomfort?
Laboratory animals 1997;31(4):318-25.
1997: Linda A Everse; I B Renes; Ina M Jürgenliemk-Schulz; DH Rutgers; MR Bernsen; Hub F J Dullens; Willem Den Otter; Jan J Battermann
Local low-dose interleukin-2 induces systemic immunity when combined with radiotherapy of cancer. A pre-clinical study.
International journal of cancer. Journal international du cancer 1997;72(6):1003-7.
1997: Annette C Moll; Dirk J Kuik; Lex Bouter; Willem Den Otter; P Dick Bezemer; Jan-Willem Koten; Saskia M Imhof; B P Kuyt; KE Tan
Incidence and survival of retinoblastoma in The Netherlands: a register based study 1862-1995.
The British journal of ophthalmology 1997;81(7):559-62.
1997: Linda A Everse; MR Bernsen; Hub F J Dullens; Willem Den Otter
Priming of the antitumor response promotes efficacy of interleukin-2 therapy.
Cancer immunology, immunotherapy : CII 1997;44(4):221-9.
1997: Leo T M van der Ven; Paul Roholl; T Gloudemans; Sylvia C van Buul-Offers; M J Welters; BA Bladergroen; J A J Faber; John S Sussenbach; Willem Den Otter
Expression of insulin-like growth factors (IGFs), their receptors and IGF binding protein-3 in normal, benign and malignant smooth muscle tissues.
British journal of cancer 1997;75(11):1631-40.
1997: Leo T M van der Ven; Sylvia C van Buul-Offers; T Gloudemans; Paul Roholl; John S Sussenbach; Willem Den Otter
Histamine-stimulated expression of insulin-like growth factors in human glioma cells.
British journal of cancer 1997;75(8):1091-7.
1996: Annette C Moll; Jan-Willem Koten; D A Lindenmayer; Linda A Everse; KE Tan; A Hamburg; J A J Faber; Willem Den Otter
Three histopathological types of retinoblastoma and their relation to heredity and age of enucleation.
Journal of medical genetics 1996;33(11):923-27.
1996: Leo T M van der Ven; Sylvia C van Buul-Offers; T Gloudemans; R J Bloemen; Paul Roholl; John S Sussenbach; Willem Den Otter
Modulation of insulin-like growth factor (IGF) action by IGF-binding proteins in normal, benign, and malignant smooth muscle tissues.
The Journal of clinical endocrinology and metabolism 1996;81(10):3629-35.
1996: Willem Den Otter; T E Merchant; D Beijerinck; Jan-Willem Koten
Breast cancer induction due to mammographic screening in hereditarily affected women.
Anticancer research 1996;16(5B):3173-5.
1996: Annette C Moll; Saskia M Imhof; L M Bouter; Dirk J Kuik; Willem Den Otter; P Dick Bezemer; Jan-Willem Koten; KE Tan
Second primary tumors in patients with hereditary retinoblastoma: a register-based follow-up study, 1945-1994.
International journal of cancer. Journal international du cancer 1996;67(4):515-9.
1996: Linda A Everse; M R Bernsen; Hub F J Dullens; Willem Den Otter
The success of locoregional, low-dose recombinant interleukin-2 therapy in tumor-bearing mice is dependent on the time of rIL-2 administration.
Journal of experimental therapeutics & oncology 1996;1(4):231-6.
1996: Annette C Moll; Saskia M Imhof; Dirk J Kuik; L M Bouter; Willem Den Otter; P Dick Bezemer; Jan-Willem Koten; KE Tan
High parental age is associated with sporadic hereditary retinoblastoma: the Dutch retinoblastoma register 1862-1994.
Human genetics 1996;98(1):109-12.
1996: Willem Den Otter; J W De Groot; M R Bernsen; A Peter M Heintz; R Maas; G J Hordijk; FW Hill; Wim R Klein; E J Ruitenberg; V P M G Rutten
Optimal regimes for local IL-2 tumour therapy.
International journal of cancer. Journal international du cancer 1996;66(3):400-3.
1996: H Voshol; Hub F J Dullens; Willem Den Otter; Johannes Vliegenthart
The glycosylation profile of interleukin-2 activated human lymphocytes correlates to their anti-tumor activity.
Anticancer research 1996;16(1):155-9.
1995: Willem Den Otter; FW Hill; Wim R Klein; Linda A Everse; E J Ruitenberg; Leo T M van der Ven; Jan-Willem Koten; Peter A Steerenberg; J A J Faber; V P M G Rutten
Ocular squamous cell carcinoma in Simmental cattle in Zimbabwe.
American journal of veterinary research 1995;56(11):1440-4.
1995: Peter A Steerenberg; L T Balemans; B H Kremer; F J Koppenhagen; P H De Mulder; Willem Den Otter
Reduction of therapeutic efficacy by a second cycle of PEG-IL-2.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1995;18(1):45-51.
1995: Willem Den Otter; FW Hill; Wim R Klein; Jan-Willem Koten; Peter A Steerenberg; P H De Mulder; C Rhode; R Stewart; J A J Faber; E J Ruitenberg
Therapy of bovine ocular squamous-cell carcinoma with local doses of interleukin-2: 67% complete regressions after 20 months of follow-up.
Cancer immunology, immunotherapy : CII 1995;41(1):10-4.
1995: M R Bernsen; Hub F J Dullens; Willem Den Otter; P M Heintz
Reevaluation of the superiority of polyethylene glycol-modified interleukin-2 over regular recombinant interleukin-2.
Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 1995;15(7):641-5.
1995: L T Balemans; Peter A Steerenberg; B H Kremer; F J Koppenhagen; P H De Mulder; Willem Den Otter
Specific tumor memory induced by polyethylene-glycol-modified interleukin-2 requires both helper and cytotoxic T cells.
Cancer immunology, immunotherapy : CII 1995;40(2):125-31.
1994: Rob Vandebriel; Roel A de Weger; Henk Van Loveren; Johan Garssen; Mireille van Poppel; Dick F van Wichen; Willem Den Otter
Specific T-cell factors that initiate cellular immune responses are produced by CD4-, CD8-, V beta 8- lymphocytes and are present in nude mice.
Cellular immunology 1994;159(1):1-14.
1994: Leo T M van der Ven; T Gloudemans; Paul Roholl; Sylvia C van Buul-Offers; BA Bladergroen; M J Welters; John S Sussenbach; Willem Den Otter
Growth advantage of human leiomyoma cells compared to normal smooth-muscle cells due to enhanced sensitivity toward insulin-like growth factor I.
International journal of cancer. Journal international du cancer 1994;59(3):427-34.
1994: L T Balemans; Peter A Steerenberg; F J Koppenhagen; B H Kremer; P H De Mulder; A M Claessen; R J Scheper; Willem Den Otter
PEG-IL-2 therapy of advanced cancer in the guinea pig. Impact of the primary tumor and beneficial effect of cyclophosphamide.
International journal of cancer. Journal international du cancer 1994;58(6):871-6.
1994: J J Bergers; Willem Den Otter; Hub F J Dullens; J W De Groot; Peter A Steerenberg; P M Filius; Daan J A Crommelin
Effect of immunomodulators on specific tumor immunity induced by liposome-encapsulated tumor-associated antigens.
International journal of cancer. Journal international du cancer 1994;56(5):721-6.
1994: M J Stassar; P D Vegt; Peter A Steerenberg; Adrian P M van der Meijden; H D Meiring; M Dessens-Kroon; H G Geertzen; Willem Den Otter
Effects of isoniazid (INH) on the BCG-induced local immune response after intravesical BCG therapy for superficial bladder cancer.
Urological research 1994;22(3):177-84.
1994: L T Balemans; P D Vegt; Peter A Steerenberg; Elizabeth C De Boer; A Van Swaaij; R E De Vries; Adrian P M van der Meijden; Willem Den Otter
Effects of sequential intravesical administration of mitomycin C and bacillus Calmette-Guérin on the immune response in the guinea pig bladder.
Urological research 1994;22(4):239-45.
1993: J J Bergers; Willem Den Otter; Hub F J Dullens; C T Kerkvliet; Daan J A Crommelin
Interleukin-2-containing liposomes: interaction of interleukin-2 with liposomal bilayers and preliminary studies on application in cancer vaccines.
Pharmaceutical research 1993;10(12):1715-21.
1993: T Gloudemans; I Pospiech; Leo T M van der Ven; Cornelis J M Lips; Willem Den Otter; John S Sussenbach
An avaII restriction fragment length polymorphism in the insulin-like growth factor II gene and the occurrence of smooth muscle tumors.
Cancer research 1993;53(23):5754-8.
1993: H Voshol; Hub F J Dullens; Willem Den Otter; Johannes Vliegenthart
Human natural killer cells: a convenient purification procedure and the influence of cryopreservation on cytotoxic activity.
Journal of immunological methods 1993;165(1):21-30.
1993: Leo T M van der Ven; I M Prinsen; G H Jansen; Paul Roholl; R Defferrari; R Slater; Willem Den Otter
Growth of cultured human glioma tumour cells can be regulated with histamine and histamine antagonists.
British journal of cancer 1993;68(3):475-83.
1993: J J Bergers; Willem Den Otter; Hub F J Dullens; J W De Groot; Peter A Steerenberg; M W Mimpen; Daan J A Crommelin
Critical factors for liposome-incorporated tumour-associated antigens to induce protective tumour immunity to SL2 lymphoma cells in mice.
Cancer immunology, immunotherapy : CII 1993;37(4):271-9.
1993: L T Balemans; V Mattijssen; Peter A Steerenberg; B E Van Driel; P H De Mulder; Willem Den Otter
Locoregional therapy with polyethylene-glycol-modified interleukin-2 of an intradermally growing hepatocellular carcinoma in the guinea pig induces T-cell-mediated antitumor activity.
Cancer immunology, immunotherapy : CII 1993;37(1):7-14.
1993: Willem Den Otter; T E Merchant; D Beijerinck; Jan-Willem Koten
Exclusion from mammographic screening of women genetically predisposed to breast cancer will probably eliminate mammographically induced breast cancer.
Anticancer research 1993;13(4):1113-5.
1993: T E Merchant; G R Thelissen; P W de Graaf; C W Nieuwenhuizen; H C Kievit; Willem Den Otter
Application of a mixed imaging sequence for MR imaging characterization of human breast disease.
Acta radiologica (Stockholm, Sweden : 1987) 1993;34(4):356-61.
1993: R A Maas; M J Becker; I S Weimar; J C De Nooy; Hub F J Dullens; Willem Den Otter
Transfer of tumor immunity by both CD4+ and CD8+ tumor infiltrating T lymphocytes activated in vivo by IL-2 therapy of tumor bearing mice.
Immunobiology 1993;188(3):281-92.
1993: M R Bernsen; H J Van Barlingen; Alike W van der Velden; Hub F J Dullens; Willem Den Otter; A Peter M Heintz
Dualistic effects of cis-diammine-dichloro-platinum on the anti-tumor efficacy of subsequently applied recombinant interleukin-2 therapy: a tumor-dependent phenomenon.
International journal of cancer. Journal international du cancer 1993;54(3):513-7.
1993: berry wilbrink; M Holewijn; J W J Bijlsma; J L van Roy; Willem Den Otter; Willem van Eden
Suppression of human cartilage proteoglycan synthesis by rheumatoid synovial fluid mononuclear cells activated with mycobacterial 60-kd heat-shock protein.
Arthritis and rheumatism 1993;36(4):514-8.
1993: H Voshol; Hub F J Dullens; Willem Den Otter; Johannes Vliegenthart
Cell surface glycoconjugates as possible target structures for human natural killer cells: evidence against the involvement of glycolipids and N-linked carbohydrate chains.
Glycobiology 1993;3(1):69-76.
1993: R A Maas; Hub F J Dullens; Willem Den Otter
Interleukin-2 in cancer treatment: disappointing or (still) promising? A review.
Cancer immunology, immunotherapy : CII 1993;36(3):141-8.
1993: M Denijn; Roel A de Weger; J A Van Unnik; Willem Den Otter; Cornelis J M Lips
Detection of calcitonin and calcitonin gene-related peptide mRNA in human medullary thyroid carcinoma. A retrospective study.
The Journal of pathology 1993;169(1):53-60.
1993: Willem Den Otter; Jan-Willem Koten; R A Maas; D J DerKinderen
Are atopic disorders due to a TH2 clone?
The British journal of dermatology 1993;128(1):102.
1993: R A Maas; Hub F J Dullens; D Henk; J Van Weering; H J De Mik; Jan-Willem Koten; R J Belger; Willem Den Otter
Histological analysis of IL-2 induced regression of murine solid SL2-tumors.
Biotherapy (Dordrecht, Netherlands) 1993;6(2):83-91.
1993: Hub F J Dullens; L H Rademakers; M Doffemont; P T Van Veen; R Bulder; Willem Den Otter
Involvement of the omental lymphoid organ in the induction of peritoneal immunity against tumor cells.
Invasion & metastasis 1993;13(5):267-76.
1992: T Gloudemans; I Pospiech; Leo T M van der Ven; Cornelis J M Lips; H Schneid; Willem Den Otter; John S Sussenbach
Expression and CpG methylation of the insulin-like growth factor II gene in human smooth muscle tumors.
Cancer research 1992;52(23):6516-21.
1992: R A Maas; P A Roest; M J Becker; I S Weimar; Hub F J Dullens; Willem Den Otter
Effector cells of low-dose IL-2 immunotherapy in tumor bearing mice: tumor cell killing by CD8+ cytotoxic T lymphocytes and macrophages.
Immunobiology 1992;186(3-4):214-29.
1992: berry wilbrink; M Holewijn; J W J Bijlsma; J L Van Roy; Ruurd van der Zee; C J Boog; Willem Den Otter; Willem van Eden
Antigen-activated T cells inhibit cartilage proteoglycan synthesis independently of T-cell proliferation.
Scandinavian journal of immunology 1992;36(5):733-43.
1992: M Denijn; Roel A de Weger; Willem Den Otter; J A van Unnik; Cornelis J M Lips
Expression of the first calcitonin/CGRP gene in spontaneous and transplanted rat medullary thyroid carcinoma: a comparison of dot-blot analysis, in situ hybridization, and immunohistochemistry.
The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society 1992;40(11):1761-7.
1992: V P M G Rutten; Wim R Klein; M A De Jong; W Quint; Willem Den Otter; E J Ruitenberg; W J Melchers
Search for bovine papilloma virus DNA in bovine ocular squamous cell carcinomas (BOSCC) and BOSCC-derived cell lines.
American journal of veterinary research 1992;53(9):1477-81.
1992: T E Merchant; D Characiejus; J N Kasimos; Willem Den Otter; L W Gierke; Thomas Glonek
Phosphodiesters in saponified extracts of human breast and colon tumors using 31P magnetic resonance spectroscopy.
Magnetic resonance in medicine : official journal of the Society of Magnetic Resonance in Medicine / Society of Magnetic Resonance in Medicine 1992;26(1):132-40.
1992: berry wilbrink; J Vernooy; Willem Den Otter; J L Van Roy; J Huber; O Huber-Bruning
Influence of rheumatoid synovial fluid and cells on proteoglycans in human cartilage explants. Modulation by piroxicam.
Clinical rheumatology 1992;11(1):86-91.
1992: J J Bergers; Willem Den Otter; J W De Groot; A W De Blois; Hub F J Dullens; Peter A Steerenberg; Daan J A Crommelin
Reconstituted membranes of tumour cells (proteoliposomes) induce specific protection to murine lymphoma cells.
Cancer immunology, immunotherapy : CII 1992;34(4):233-40.
1991: T E Merchant; G R Thelissen; P W de Graaf; Willem Den Otter; Thomas Glonek
Clinical magnetic resonance spectroscopy of human breast disease.
Investigative radiology 1991;26(12):1053-9.
1991: H J De Mik; Jan-Willem Koten; R A Maas; Hub F J Dullens; Willem Den Otter
Tumour regression by IL-2 mediated stagnation of blood flow.
In vivo (Athens, Greece) 1991;5(6):679-84.
1991: R A Maas; Hub F J Dullens; Willem Den Otter
Mechanisms of tumor regression induced by low doses of interleukin-2.
In vivo (Athens, Greece) 1991;5(6):637-41.
1991: Willem Den Otter; R A Maas; Jan-Willem Koten; Hub F J Dullens; M Bernsen; Wim R Klein; V P M G Rutten; Peter A Steerenberg; L Balemans; E J Ruitenberg
Effective immunotherapy with local low doses of interleukin-2.
In vivo (Athens, Greece) 1991;5(6):561-5.
1991: Hub F J Dullens; J C Wind; R A Maas; M R Bernsen; I M Vulto; L H Rademakers; Willem Den Otter
Lymphokine-activated killer-cell-mediated killing of WiDr colon carcinoma cells is inhibited by K562 erythroleukemia cells.
International immunology 1991;3(10):959-64.
1991: T E Merchant; P W de Graaf; C W Nieuwenhuizen; H C Kievit; C J Bakker; Willem Den Otter
Fibroadenoma of the breast: in vivo magnetic resonance characterization.
European journal of radiology 1991;13(2):91-5.
1991: berry wilbrink; J J Nietfeld; Willem Den Otter; J L van Roy; J W J Bijlsma; O Huber-Bruning
Role of TNF alpha, in relation to IL-1 and IL-6 in the proteoglycan turnover of human articular cartilage.
British journal of rheumatology 1991;30(4):265-71.
1991: T E Merchant; P Meneses; L W Gierke; Willem Den Otter; Thomas Glonek
31P magnetic resonance phospholipid profiles of neoplastic human breast tissues.
British journal of cancer 1991;63(5):693-8.
1991: V P M G Rutten; W A De Jong; Wim R Klein; Willem Den Otter; Peter A Steerenberg; E J Ruitenberg
Immunotherapy of bovine ocular squamous cell carcinoma: isolation, culture and characterization of lymphocytes present in the tumor.
Anticancer research 1991;11(3):1259-64.
1991: Jan-Willem Koten; Willem Den Otter
The transition of benign to malignant in epithelial and mesenchymal tumours.
Anticancer research 1991;11(2):567-8.
1991: M Denijn; Roel A de Weger; Cornelis J M Lips; J A Van Unnik; Willem Den Otter
Hybridohistochemical demonstration of alternative splicing of the CALC-I gene.
The American journal of pathology 1991;138(2):273-7.
1991: R A Maas; D H Van Weering; Hub F J Dullens; Willem Den Otter
Intratumoral low-dose interleukin-2 induces rejection of distant solid tumour.
Cancer immunology, immunotherapy : CII 1991;33(6):389-94.
1991: Peter A Steerenberg; W H De Jong; E Geerse; A De Graaf; R J Scheper; Willem Den Otter; E J Ruitenberg
Major histocompatibility complex class II antigen expression on leucocyte subpopulations in the draining lymph node and tumour in the early phase of bacillus-Calmette-Guérin-induced tumour regression.
Cancer immunology, immunotherapy : CII 1991;33(3):189-97.
1991: Hub F J Dullens; L H Rademakers; S Cluistra; R Van Os; K Dux; P J Den Besten; Willem Den Otter
Parathymic lymph nodes during growth and rejection of intraperitoneally inoculated tumor cells.
Invasion & metastasis 1991;11(4):216-26.
1991: Peter A Steerenberg; E Geerse; W H De Jong; R Burger; R J Scheper; Willem Den Otter
Tumour rejection after adoptive transfer of line-10-immune spleen cells is mediated by two T cell subpopulations.
Cancer immunology, immunotherapy : CII 1991;34(2):103-10.
1991: V P M G Rutten; Wim R Klein; W A De Jong; W Misdorp; Peter A Steerenberg; W H De Jong; Willem Den Otter; E J Ruitenberg
Immunotherapy of bovine ocular squamous cell carcinoma by repeated intralesional injections of live bacillus Calmette-Guérin (BCG) or BCG cell walls.
Cancer immunology, immunotherapy : CII 1991;34(3):186-90.
1990: D J DerKinderen; Jan-Willem Koten; KE Tan; F A Beemer; L K Van Romunde; Willem Den Otter
Parental age in sporadic hereditary retinoblastoma.
American journal of ophthalmology 1990;110(6):605-9.
1990: J J Nietfeld; berry wilbrink; M Helle; J L van Roy; Willem Den Otter; A J Swaak; O Huber-Bruning
Interleukin-1-induced interleukin-6 is required for the inhibition of proteoglycan synthesis by interleukin-1 in human articular cartilage.
Arthritis and rheumatism 1990;33(11):1695-701.
1990: T Gloudemans; I Prinsen; J A Van Unnik; Cornelis J M Lips; Willem Den Otter; John S Sussenbach
Insulin-like growth factor gene expression in human smooth muscle tumors.
Cancer research 1990;50(20):6689-95.
1990: J J Nietfeld; berry wilbrink; Willem Den Otter; J Huber; O Huber-Bruning
The effect of human interleukin 1 on proteoglycan metabolism in human and porcine cartilage explants.
The Journal of rheumatology 1990;17(6):818-26.
1990: berry wilbrink; J W J Bijlsma; O Huber-Bruning; J L Van Roy; Willem Den Otter; Willem van Eden
Mycobacterial antigens stimulate rheumatoid mononuclear cells to cartilage proteoglycan depletion.
The Journal of rheumatology 1990;17(4):532-7.
1990: D J Derkinderen; O J Boxma; Jan-Willem Koten; Willem Den Otter
Stochastic theory of oncogenesis.
Anticancer research 1990;10(2B):497-504.
1990: Willem Den Otter; Jan-Willem Koten; B J Van der Vegt; F A Beemer; O J Boxma; P W De Graaf; D J Derkinderen; FW Hill; J Huber; Wim R Klein
Hereditary cancer and its clinical implications: a view.
Anticancer research 1990;10(2B):489-95.
1990: Willem Den Otter; Jan-Willem Koten; B J Van der Vegt; F A Beemer; O J Boxma; D J Derkinderen; P W De Graaf; J Huber; C J Lips; Paul Roholl
Oncogenesis by mutations in anti-oncogenes: a view.
Anticancer research 1990;10(2B):475-87.
1990: Peter A Steerenberg; W H De Jong; E Geerse; A Beuvink; R J Scheper; Willem Den Otter; E J Ruitenberg
Major-histocompatibility-complex-class-II-positive cells and interleukin-2-dependent proliferation of immune T cells are required to reject carcinoma cells in the guinea pig.
Cancer immunology, immunotherapy : CII 1990;31(5):297-304.
1990: Dainius Characiejus; Hub F J Dullens; Willem Den Otter
Mechanisms of tumour rejection in the murine DBA/2-SL2 concomitant immunity system.
Cancer immunology, immunotherapy : CII 1990;32(3):179-84.
1990: Peter A Steerenberg; W H De Jong; A Elgersma; R Burger; L G Poels; A M Claessen; Willem Den Otter; E J Ruitenberg
Tumor infiltrating leukocytes (tils) during progressive tumor growth and BCG-mediated tumor regression.
Virchows Archiv. B, Cell pathology including molecular pathology 1990;59(4):185-94.
1990: Peter A Steerenberg; W H De Jong; E Geerse; B J Aleva; C M Besselink; B T Van Rens; V P M G Rutten; L G Poels; R J Scheper; Willem Den Otter
Major histocompatibility complex class II antigen expression during potentiation of line-10 tumor immunity after intralesional administration of bacillus Calmette-Guérin.
Cancer immunology, immunotherapy : CII 1990;32(2):95-104.
1989: R A Maas; Hub F J Dullens; W H De Jong; Willem Den Otter
Immunotherapy of mice with a large burden of disseminated lymphoma with low-dose interleukin 2.
Cancer research 1989;49(24 Pt 1):7037-40.
1989: D J DerKinderen; Jan-Willem Koten; L K Van Romunde; N J Nagelkerke; KE Tan; F A Beemer; Willem Den Otter
Early diagnosis of bilateral retinoblastoma reduces death and blindness.
International journal of cancer. Journal international du cancer 1989;44(1):35-9.
1989: Rob Vandebriel; R A De Weger; Gerrit Los; H Van Loveren; G J Wiegers; P A Oude Weernink; Willem Den Otter
Two specific T cell factors that initiate immune responses in murine allograft systems. A comparison of biologic functions.
Journal of immunology (Baltimore, Md. : 1950) 1989;143(1):66-73.
1989: V P M G Rutten; Wim R Klein; W A De Jong; W Misdorp; Willem Den Otter; Peter A Steerenberg; W H De Jong; E J Ruitenberg
Local interleukin-2 therapy in bovine ocular squamous cell carcinoma. A pilot study.
Cancer immunology, immunotherapy : CII 1989;30(3):165-9.
1989: Hub F J Dullens; Roel A de Weger; M Van der Maas; P J Den Besten; Rob Vandebriel; Willem Den Otter
Production of specific macrophage-arming factor precedes cytotoxic T lymphocyte activity in vivo during tumor rejection.
Cancer immunology, immunotherapy : CII 1989;30(1):28-33.
1989: Roel A de Weger; Rob Vandebriel; H Slager; D Mans; Henk Van Loveren; berry wilbrink; Hub F J Dullens; Willem Den Otter
Initial immunochemical characterization of specific macrophage-arming factor.
Cancer immunology, immunotherapy : CII 1989;30(1):21-7.
1988: D J DerKinderen; Jan-Willem Koten; N J Nagelkerke; KE Tan; F A Beemer; Willem Den Otter
Non-ocular cancer in patients with hereditary retinoblastoma and their relatives.
International journal of cancer. Journal international du cancer 1988;41(4):499-504.
1988: Jan-Willem Koten; D J DerKinderen; Willem Den Otter
Bone sarcomas linked to radiotherapy and chemotherapy in children.
The New England journal of medicine 1988;318(9):581-2.
1988: Willem Den Otter; Jan-Willem Koten; D J DerKinderen; KE Tan
Number of events in tumorigenesis.
Lancet 1988;1(8582):412-3.
1987: Jan-Willem Koten; D J Derkinderen; Willem Den Otter
Pathogenesis of Burkitt's lymphoma in children.
Anticancer research 1987;7(4B):869.
1987: D J Derkinderen; Jan-Willem Koten; R Wolterbeek; F A Beemer; KE Tan; Willem Den Otter
Non-ocular cancer in hereditary retinoblastoma survivors and relatives.
Ophthalmic paediatrics and genetics 1987;8(1):23-5.
1987: Roel A de Weger; berry wilbrink; R M Moberts; D Mans; R Oskam; Willem Den Otter
Immune reactivity in SL2 lymphoma-bearing mice compared with SL2-immunized mice.
Cancer immunology, immunotherapy : CII 1987;24(1):25-36.
1987: O Huber-Bruning; berry wilbrink; J E Vernooij; J W J Bijlsma; Willem Den Otter; J Huber
Differential responses of old human cartilage explants to synovial- and mononuclear-cell factors.
Rheumatology international 1987;7(5):223-9.
1986: D J DerKinderen; Jan-Willem Koten; Willem Den Otter; KE Tan; F A Beemer
Retinoblastoma, melanoma, and pancreatic cancer.
Lancet 1986;2(8519):1335-6.
1986: O Huber-Bruning; berry wilbrink; J E Vernooij; J W J Bijlsma; Willem Den Otter; J Huber
Contrasting reactivity of young and old human cartilage to mononuclear cell factors.
The Journal of rheumatology 1986;13(6):1191-2.
1986: O Huber-Bruning; berry wilbrink; J E Vernooij; J W J Bijlsma; Willem Den Otter; J Huber
Contrasting in vitro effects of retinol and mononuclear cell factor on young and old human cartilage.
The Journal of pathology 1986;150(1):21-7.
1986: D J DerKinderen; Jan-Willem Koten; F A Beemer; KE Tan; Willem Den Otter
Second nonocular tumors in retinoblastoma survivors: are they radiation-induced?
Ophthalmology 1986;93(8):1124-5.
1986: Willem Den Otter; Jan-Willem Koten; D J Derkinderen
A new model for oncogenesis. From tumour immunology to a mathematical approach of oncogenesis.
Anticancer research 1986;6(3 Pt B):509-14.
1986: Hub F J Dullens; W Vuist; M Van der Maas; Willem Den Otter
The role of host lymphocytes and host macrophages in antitumor reactions after injection of sensitized lymphocytes and tumor target cells into naive mice.
Cancer immunology, immunotherapy : CII 1986;23(2):113-8.
1986: Hub F J Dullens; S Schakenraad; A Oostdijk; W Vuist; M Van der Maas; Willem Den Otter
Specific tumoricidal activity of cytotoxic macrophages and cytotoxic lymphocytes.
Cancer immunology, immunotherapy : CII 1986;22(2):100-6.
1985: A A Dogterom; O Huber-Bruning; J E Vernooy; berry wilbrink; Willem Den Otter; J Huber
Matrix depletion of young and old human articular cartilage by cultured autologous synovium fragments: a chondrocyte-independent effect.
Rheumatology international 1985;5(4):169-73.
1984: H van Loveren; J W de Groot; Jan-Willem Koten; A H Piersma; R A de Weger; Willem Den Otter
A macrophage factor enhancing the systemic anti-tumour effect of T lymphocytes.
Immunobiology 1984;166(2):118-30.
1983: Willem Den Otter; J W De Groot; Hub F J Dullens
Eradication of tumor cells after injection into immunized hosts compared with the eradication of tumor cells after transfer of immune peritoneal exudates into tumor-bearing recipients.
Cancer immunology, immunotherapy : CII 1983;16(2):72-6.
1982: E De Heer; J W De Groot; Willem Den Otter; Hub F J Dullens
Peritoneal cell populations during tumour injection.
International journal of tissue reactions 1982;4(1):81-90.
1980: E Pels; J W De Groot; R Mullink; J A Van Unnik; Willem Den Otter
Identification of two different types of mouse peritoneal exudate cells with ring-shaped nuclei.
Journal of the Reticuloendothelial Society 1980;27(4):367-76.